Clinicopathological evaluation of renal allograft treated with anti-CD25 monoclonal antibody

被引:7
|
作者
Okamoto, M [1 ]
Akioka, K
Higuchi, A
Kadotani, Y
Ushigome, H
Uryuhara, K
Kaihara, S
Yoshimura, N
机构
[1] Kyoto Prefectural Univ Med, Dept Organ Interact Res Med, Kamigyo Ku, Kyoto 6028566, Japan
[2] Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Transplantat & Regenerat Surg, Kyoto 6028566, Japan
关键词
anti-CD25 monoclonal antibody; kidney transplantation; protocol biopsy;
D O I
10.1111/j.1399-0012.2005.00404.x
中图分类号
R61 [外科手术学];
学科分类号
摘要
Twenty-seven living-donor kidney recipients were treated with the antibody against CD25 as the induction immunosuppressive agent. They did not develop acute rejection within 1 month after transplantation, and mean serum creatinine level at 1 month was 1.0 +/- 0.4 mg/dL. There were no findings of acute rejection or drug-induced nephrotoxity in protocol biopsies at 1 month following transplantation. After 1 month had passed, acute rejection occurred in three cases. The pathological grade of acute rejection varied from borderline to grade III by Banff classification. The careful inspection is necessary to find out the occurrences of acute rejection more than 2 months after transplantation because immunological situation has been changing around this period.
引用
收藏
页码:49 / 53
页数:5
相关论文
共 50 条
  • [41] ANTI-CD25 MONOCLONAL-ANTIBODY PREVENTS EARLY REJECTION IN LIVER-TRANSPLANTATION - A PILOT-STUDY
    OTTO, G
    THIES, J
    KABELITZ, D
    SCHLAG, H
    HOFMANN, WJ
    HERFARTH, C
    MEUER, S
    TRANSPLANTATION PROCEEDINGS, 1991, 23 (01) : 1387 - 1389
  • [42] Short-term anti-CD25 monoclonal antibody treatment and neogenetic CD4+CD25high regulatory T cells in kidney transplantation
    Wang, Zhen
    Xiao, Li
    Shi, Bing-Yi
    Qian, Ye-Yong
    Bai, Hong-Wei
    Chang, Jing-Yuan
    Cai, Ming
    TRANSPLANT IMMUNOLOGY, 2008, 19 (01) : 69 - 73
  • [43] Effect of anti-CD25 antibodies on T regulatory cells in islet allograft recipients
    Hire, Kelly
    Bansal-Pakala, Pratima
    Hering, Bernhard
    XENOTRANSPLANTATION, 2007, 14 (05) : 476 - 477
  • [44] Targeting activated T cells: successful use of anti-CD25 monoclonal antibody basiliximab in a patient with systemic sclerosis
    Scherer, H. U.
    Burmester, G-R
    Riemekasten, G.
    ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 (09) : 1245 - 1247
  • [45] Ongoing, open, prospective pilot trial in systemic sclerosis using anti-CD25 monoclonal antibody basiliximalb targeting
    Bruckner, C. S.
    Hanitsch, L. G.
    Schmidt, K.
    Burmester, G. R.
    Riemekasten, G.
    ZEITSCHRIFT FUR RHEUMATOLOGIE, 2007, 66 : 70 - 71
  • [46] Targeting T-cells: Successful use of anti-CD25 monoclonal antibody basiliximab in a patient with systemic sclerosis
    Scherer, HU
    Burmester, GR
    Riemekasten, G
    ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 : 303 - 303
  • [47] Comment on "cutting edge:: Anti-CD25 monoclonal antibody injection results in the functional inactivation, not depletion, CD4+CD25+ T regulatory cells"
    Zelenay, Santiago
    Demengeot, Jocelyne
    JOURNAL OF IMMUNOLOGY, 2006, 177 (04): : 2036 - 2037
  • [48] Chimeric anti-CD25 antibody in the treatment of refractory fulminating ulcerative colitis
    Oliver-Goicolea, P.
    Irastorza-Terradillos, I.
    Vitoria-Cormenzana, J. C.
    ANALES DE PEDIATRIA, 2011, 74 (05): : 340 - 341
  • [49] Management of fulminating ulcerative colitis in childhood with chimeric anti-CD25 antibody
    Schwarzer, A
    Ricciardelli, I
    Kirkham, S
    Binnie, K
    Shah, N
    Elawad, MA
    Hill, SM
    Furman, M
    Smith, VV
    Sebire, N
    Milla, PJ
    Londei, M
    Lindley, KJ
    JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2006, 42 (02): : 245 - 248
  • [50] Response to comment on "cutting edge:: Anti-CD25 monoclonal antibody injection results in the functional inactivation, not depletion, of CD4+CD25+ T regulatory cells"
    Kohm, Adam P.
    Miller, Stephen D.
    JOURNAL OF IMMUNOLOGY, 2006, 177 (04): : 2037 - 2038